Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,154 Mln
P/E Ratio
--
P/B Ratio
5.7
Industry P/E
--
Debt to Equity
0.44
ROE
-0.62 %
ROCE
-38.44 %
Div. Yield
0 %
Book Value
1.38
EPS
-1.08
CFO
$-544.39 Mln
EBITDA
$-889.64 Mln
Net Profit
$-861.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corp (ADPT)
| 23.94 | -3.13 | -3.63 | 170.18 | -3.43 | -25.57 | -- |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corp (ADPT)
| 22.15 | -35.86 | -72.77 | -52.55 | 97.63 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.70 | 10,593.45 | 21.84 | 23.13 | |
| 304.14 | 8,570.17 | 22.78 | 66.44 | |
| 28.24 | 10,589.59 | -- | -28.77 | |
| 106.58 | 10,559.67 | 32.44 | 14.16 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry,... computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Address: 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 Read more
Co-Founder, CEO & Chairman
Mr. Chad M. Robins M.B.A.
Co-Founder, CEO & Chairman
Mr. Chad M. Robins M.B.A.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adaptive Biotechnologies Corp (ADPT) stood at $ 539 Mln as on 31-Dec-24
The share price of Adaptive Biotechnologies Corp (ADPT) is $7.43 (NASDAQ) as of 30-Apr-2025 14:43 EDT. Adaptive Biotechnologies Corp (ADPT) has given a return of -3.43% in the last 3 years.
Adaptive Biotechnologies Corp (ADPT) has a market capitalisation of $ 1,154 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Adaptive Biotechnologies Corp (ADPT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adaptive Biotechnologies Corp (ADPT) and enter the required number of quantities and click on buy to purchase the shares of Adaptive Biotechnologies Corp (ADPT).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Address: 1165 Eastlake Avenue East, Seattle, WA, United States, 98109
The CEO & director of Mr. Chad M. Robins M.B.A.. is Adaptive Biotechnologies Corp (ADPT), and CFO & Sr. VP is Mr. Chad M. Robins M.B.A..
There is no promoter pledging in Adaptive Biotechnologies Corp (ADPT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Adaptive Biotechnologies Corp (ADPT) | Ratios |
|---|---|
|
Return on equity(%)
|
-62.41
|
|
Operating margin(%)
|
-82.71
|
|
Net Margin(%)
|
-89.12
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adaptive Biotechnologies Corp (ADPT) was $0 Mln.
$-0.18
(
